Sertraline-Induced Urinary Retention Reversed by Mirtazapine in an Adolescent

References (7)

1. Verhamme KM, Sturkenboom MC, Stricker BH, et al. Drug-induced urinary retention: incidence, management and prevention. Drug Saf. 2008;31(5):373–388. PubMed CrossRef
2. Drake MJ, Nixon PM, Crew JP. Drug-induced bladder and urinary disorders: incidence, prevention and management. Drug Saf. 1998;19(1):45–55. PubMed CrossRef
3. Thor KB. Serotonin and norepinephrine involvement in efferent pathways to the urethral rhabdosphincter: implications for treating stress urinary incontinence. Urology. 2003;62(suppl 1):3–9. PubMed CrossRef
4. Padala PR, Sadiq HJ, Padala KP. Urinary obstruction with citalopram and aripiprazole combination in an elderly patient. J Clin Psychopharmacol. 2006;26(6):667–668. PubMed CrossRef
5. Daws LC, Gould GG. Ontogeny and regulation of the serotonin transporter: providing insights into human disorders. Pharmacol Ther. 2011;131(1):61–79. PubMed CrossRef
6. Davis R, Wilde MI. Mirtazapine: a review of its pharmacology and therapeutic potential in the management of major depression. CNS Drugs. 1996;5(5):389–402. PubMed CrossRef
7. Stimmel GL, Dopheide JA, Stahl SM. Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects. Pharmacotherapy. 1997;17(1):10–21. PubMed CrossRef